Indirect, paracrine-mediated modulation of immune cells, fibroblasts, and chondrocytes

Indirect, paracrine-mediated modulation of immune cells, fibroblasts, and chondrocytes refers to the primary therapeutic mechanism of Mesenchymal Stem Cells (MSCs) and related cell therapies. Rather than acting through a single receptor, this process involves the secretion of a complex "secretome" consisting of cytokines, chemokines, growth factors, and extracellular vesicles (Gnecchi et al., 2016, PubMed). These factors work in concert to polarize macrophages toward an anti-inflammatory phenotype, inhibit T-cell proliferation, and stimulate chondrocyte matrix production while regulating fibroblast activity to prevent fibrosis (Wang et al., 2014, NIH). This multifaceted approach is particularly relevant in treating degenerative joint diseases like osteoarthritis and systemic inflammatory conditions where a single-target drug may be insufficient (Caplan, 2017, PubMed). Because it represents a physiological process involving hundreds of signaling molecules, it is not classified as a discrete molecular target but rather a systems-level therapeutic effect. Clinical applications of this mechanism are currently being explored through the administration of live MSCs or their isolated exosomes to promote tissue regeneration (Vizoso et al., 2017, peer-reviewed journal).

Other names

Mesenchymal stem cell paracrine signalingMSC secretome-mediated immunomodulationTrophic modulation of the microenvironmentParacrine-mediated tissue repair

Secretion of a complex secretome consisting of cytokines, growth factors, and extracellular vesicles that collectively suppress inflammation and promote tissue regeneration.